| Name | Title | Contact Details |
|---|
MS Transverse Insurance Group is a property and casualty program carrier based in Princeton, New Jersey. As a subsidiary of Mitsui Sumitomo Insurance Group and part of MS&AD Insurance Group Holdings, it operates as a hybrid fronting carrier. Founded in 2018, the company specializes in program administration, reinsurance partnerships, and alternative capital solutions, serving as a link between reinsurers, program administrators, and Managing General Agents (MGAs). The company offers a range of services, including program administration for niche risks, reinsurance solutions with over 100 reinsurer relationships, flexible risk retention structures, and fronting services that ensure regulatory compliance and claims management. MS Transverse is recognized for its strong financial standing, holding an A (Excellent) rating from A.M. Best, and has been named Fronting Carrier of the Year in 2022 and 2024. With offices in New York, New Jersey, and Texas, it ranks among the top 10 U.S. fronting carriers by direct premiums written.
RCB Bank Ltd, based in Cyprus, was established in 1995 and is known for enhancing economic ties between Russia and Europe. Originally named Russian Commercial Bank (Cyprus) Limited, it received its banking license from the Central Bank of Cyprus. The bank offers a range of typical commercial banking services, likely including corporate and retail banking, investment services, and international transactions. RCB Bank Ltd has expanded its presence in Cyprus with branches in Limassol and Nicosia. RCB Bank, located in Claremore, Oklahoma, was founded in 1936 and has grown to become one of the largest Oklahoma-owned banks. It provides personal and business banking services, loans, and investment products across over 50 locations in Oklahoma and Kansas. The bank emphasizes building strong relationships with its customers and actively participates in community events.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
ePayPolicy is the fastest, easiest and most secure way to move money in the insurance industry. Its never been easier to get paid. There are no contracts, no setup fees, and no hidden fees. Best of all, there is no technical work required to get up and running. Sign up takes only 5 minutes at epaypolicy.com and well have you ready to accept payments online within 24 hours.